Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-asparaginase + erwinia asparaginase
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular
01
Overview
L-asparaginase + erwinia asparaginase is a **combination drug** consisting of two asparaginase enzymes, both used as antineoplastic agents in the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). L-asparaginase is typically derived from Escherichia coli, while erwinia asparaginase is produced from Erwinia chrysanthemi. Both enzymes deplete asparagine, an amino acid necessary for the survival of leukemic cells, by catalyzing its hydrolysis to aspartic acid and ammonia. Leukemic lymphoblasts are unable to synthesize asparagine sufficiently and undergo apoptosis when asparagine is depleted. Erwinia asparaginase is often used as a substitute for patients who develop hypersensitivity to E. coli-derived asparaginase. Both forms are administered by intravenous or intramuscular injection as part of multi-agent chemotherapy regimens[1][2][3][4][5][6][7].
- Other names
- L-asparaginase + erwinia asparaginaseE. coli asparaginase + Erwinia asparaginase
Beyond the preview
Go deeper on L-asparaginase + erwinia asparaginase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-asparaginase + erwinia asparaginase.